尼拉帕尼：聚腺苷二磷酸-核糖聚合酶抑制剂

尼拉帕尼（Niraparib，商品名Zejula^TM）是聚腺苷二磷酸-核糖聚合酶（PARP）的口服小分子抑制剂，PARP抑制是治疗由DNA修复基因（如BRCA1和BRCA2）特异性畸变引起的DNA修复机制缺陷的癌症的有效策略。尼拉帕尼于2017年3月在美国获批，维持治疗复发性上皮性卵巢癌、输卵管癌、原发性腹膜癌的成年患者，这些患者对铂类化疗有完全或部分反应，推荐剂量为口服300 mg/d，直到疾病发生恶化或产生无法接受的不良反应。临床研究结果表明该药可以延长患者的无恶化生存期，为治疗卵巢癌提供了有效和可靠的治疗手段。

Niraparib:poly (adenosine diphosphate-ribose) polymerase inhibitor

Niraparib is an oral small molecule inhibitor of poly(ADP-ribose) polymerase (PARP). PARP inhibition is an effective strategy for the treatment of cancers with deficienty in DNA repair mechanisms induced by specific aberrations of DNA repair genes (eg. BRCA1 and BRCA2). Niraparib was approved in the United States in March 2017 for maintenance treatment of adult patients with recurrent epithelial ovarian cancer, fallopian tubes cancer, and primary peritoneal cancer. These patients have a complete or partial response to platinum-based chemotherapy. The recommended dose is 300 mg/d until the diseases worsen or produce unacceptable adverse reactions. The results of clinical studies show that Niraparib can prolong the patient''s non-progressive survival and provide an effective and reliable treatment for ovarian cancer.